“we're developing this conduction system pacing product here, which we're targeting to start up pivotal call in 2026.”

In context

“not just in single but without a doubt in dual chamber. So we're seeing an increase in the number of accounts from a year ago. We've seen an increase in the amount of physicians that have been trained that that's increased, like by 50%, I think it was the last time I saw it. The implants per day have doubled as a result of that. So I think it's going very well. And I think I expect to see this outer performance continue here in the next kind of several years. One of the things that we're also doing to kind of be able to support that, and I said that in my prepared comments, was we got to continue to innovate here if we want to be able to kind of support that growth, right? So we'll launch a next-generation over that's got a 25% longer battery life. That's going to add another 2 years, and we're developing this conduction system pacing product here, which we're targeting to start up pivotal call in 2026. And I think given the excitement that we have with the product, I think it's -- I think we're going to see kind of good enrollment there, too. So -- and then on top of that, we're rolling it out internationally too, right? So right now, it's -- it's launched in 50 countries. Some of them have been launched for a year or 2 years. Some of them were just in the process of launching. So I think there's a lot of good momentum here with this portfolio, not just in terms of execution out in the market, but also in terms of R&D and clinical work. Vijay Kumar: That's helpful. And maybe one P&L on the EPS guidance here. The top end was lowered by $0.05 and [ midpoint ] was maintained despite, I think, operating margins tweak down, organic coming down, where are the offsets here? Maybe some comment”